|
Binovi Announces Board and Management Changes
|
|
Binovi Technologies Corp
|
Jul 13, 2021 07:45AM
|
|
Binovi Announces Management and Board Changes
|
|
Binovi Technologies Corp
|
Sep 21, 2021 07:30AM
|
|
Binovi chairman Booth resigns
|
|
Binovi Technologies Corp
|
Feb 07, 2022 05:59PM
|
|
Binovi Focusing on eSports Athletes
|
|
Binovi Technologies Corp
|
Jul 08, 2021 08:45AM
|
|
Binovi grants options to buy 2.64 million shares
|
|
Binovi Technologies Corp
|
May 18, 2022 05:43PM
|
|
Binovi receives management cease trade order
|
|
Binovi Technologies Corp
|
Jun 30, 2021 02:42AM
|
|
Binovi Technologies arranges 1:10 share rollback
|
|
Binovi Technologies Corp
|
Oct 13, 2021 03:31PM
|
|
Binovi Technologies Corp Responds to Unsolicited Captiva Verde Bid
|
|
Binovi Technologies Corp
|
Aug 16, 2021 05:15PM
|
|
BINOVI TECHNOLOGIES CORP. ANNOUNCES NON-BROKERED COMMON SHARE PRIVATE PLACEMENT
|
|
Binovi Technologies Corp
|
Nov 18, 2021 07:24PM
|
|
Binovi Technologies Files Annual Financial Statements
|
|
Binovi Technologies Corp
|
Jul 28, 2021 08:15AM
|
|
Biomind Announces Voting Results From the 2023 Annual Meeting of Shareholders
|
|
Biomind Labs Inc
|
Jun 30, 2023 06:55AM
|
|
Biomind Labs and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production...
|
|
Biomind Labs Inc
|
Sep 27, 2022 06:26AM
|
|
Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
|
|
Biomind Labs Inc
|
Sep 21, 2022 06:25AM
|
|
Biomind Labs Announces DTC Eligibility in the United States
|
|
Biomind Labs Inc
|
Feb 24, 2022 08:12AM
|
|
Biomind Labs Announces FDA Investigational New Drug Clearance for Its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression...
|
|
Biomind Labs Inc
|
Nov 14, 2022 09:13PM
|
|
Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression
|
|
Biomind Labs Inc
|
Nov 04, 2022 07:58AM
|
|
Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07
|
|
Biomind Labs Inc
|
Mar 03, 2022 07:30AM
|
|
Biomind Labs Announces Pre-IND Meeting Request Granted by FDA for Its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression
|
|
Biomind Labs Inc
|
Oct 11, 2022 12:38PM
|
|
Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety…
|
|
Biomind Labs Inc
|
Dec 28, 2022 09:22AM
|
|
Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease…
|
|
Biomind Labs Inc
|
Apr 25, 2023 10:32AM
|
